GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003139728 | Skin | AK | negative regulation of protein ubiquitination | 30/1910 | 83/18723 | 2.29e-10 | 3.01e-08 | 30 |
GO:200123428 | Skin | AK | negative regulation of apoptotic signaling pathway | 55/1910 | 224/18723 | 4.38e-10 | 5.24e-08 | 55 |
GO:190332128 | Skin | AK | negative regulation of protein modification by small protein conjugation or removal | 32/1910 | 95/18723 | 4.71e-10 | 5.26e-08 | 32 |
GO:190336428 | Skin | AK | positive regulation of cellular protein catabolic process | 43/1910 | 155/18723 | 6.24e-10 | 6.48e-08 | 43 |
GO:006156416 | Skin | AK | axon development | 91/1910 | 467/18723 | 8.60e-10 | 8.63e-08 | 91 |
GO:000989627 | Skin | AK | positive regulation of catabolic process | 94/1910 | 492/18723 | 1.32e-09 | 1.26e-07 | 94 |
GO:005067319 | Skin | AK | epithelial cell proliferation | 86/1910 | 437/18723 | 1.52e-09 | 1.43e-07 | 86 |
GO:000030227 | Skin | AK | response to reactive oxygen species | 53/1910 | 222/18723 | 2.63e-09 | 2.33e-07 | 53 |
GO:000697928 | Skin | AK | response to oxidative stress | 86/1910 | 446/18723 | 4.23e-09 | 3.30e-07 | 86 |
GO:007259426 | Skin | AK | establishment of protein localization to organelle | 81/1910 | 422/18723 | 1.48e-08 | 9.11e-07 | 81 |
GO:200123520 | Skin | AK | positive regulation of apoptotic signaling pathway | 35/1910 | 126/18723 | 2.31e-08 | 1.29e-06 | 35 |
GO:200123627 | Skin | AK | regulation of extrinsic apoptotic signaling pathway | 39/1910 | 151/18723 | 3.37e-08 | 1.80e-06 | 39 |
GO:003133127 | Skin | AK | positive regulation of cellular catabolic process | 80/1910 | 427/18723 | 5.42e-08 | 2.76e-06 | 80 |
GO:006219728 | Skin | AK | cellular response to chemical stress | 66/1910 | 337/18723 | 1.46e-07 | 6.32e-06 | 66 |
GO:002261217 | Skin | AK | gland morphogenesis | 32/1910 | 118/18723 | 1.68e-07 | 7.09e-06 | 32 |
GO:005067818 | Skin | AK | regulation of epithelial cell proliferation | 72/1910 | 381/18723 | 1.76e-07 | 7.28e-06 | 72 |
GO:003052226 | Skin | AK | intracellular receptor signaling pathway | 55/1910 | 265/18723 | 2.26e-07 | 9.03e-06 | 55 |
GO:004887228 | Skin | AK | homeostasis of number of cells | 56/1910 | 272/18723 | 2.33e-07 | 9.18e-06 | 56 |
GO:003017717 | Skin | AK | positive regulation of Wnt signaling pathway | 35/1910 | 140/18723 | 3.93e-07 | 1.48e-05 | 35 |
GO:004211019 | Skin | AK | T cell activation | 85/1910 | 487/18723 | 5.16e-07 | 1.85e-05 | 85 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa05020210 | Esophagus | ESCC | Prion disease | 193/4205 | 273/8465 | 6.42e-13 | 1.34e-11 | 6.89e-12 | 193 |
hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa05170210 | Esophagus | ESCC | Human immunodeficiency virus 1 infection | 147/4205 | 212/8465 | 3.37e-09 | 3.53e-08 | 1.81e-08 | 147 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa0513526 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
hsa05171211 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNF | SNV | Missense_Mutation | rs373646181 | c.481N>A | p.Val161Ile | p.V161I | P01375 | protein_coding | tolerated(0.2) | benign(0) | TCGA-CM-4752-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | novel | c.186N>T | p.Glu62Asp | p.E62D | P01375 | protein_coding | tolerated(0.08) | possibly_damaging(0.67) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | rs369510319 | c.473N>A | p.Arg158His | p.R158H | P01375 | protein_coding | deleterious(0.03) | probably_damaging(0.98) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | rs373646181 | c.481N>A | p.Val161Ile | p.V161I | P01375 | protein_coding | tolerated(0.2) | benign(0) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | novel | c.607N>A | p.Glu203Lys | p.E203K | P01375 | protein_coding | tolerated(0.13) | benign(0.031) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | novel | c.341N>T | p.Ala114Val | p.A114V | P01375 | protein_coding | tolerated(0.16) | benign(0.267) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TNF | SNV | Missense_Mutation | rs777874746 | c.169G>A | p.Gly57Ser | p.G57S | P01375 | protein_coding | deleterious(0.03) | probably_damaging(0.995) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
TNF | insertion | Frame_Shift_Ins | novel | c.315_316insGGTTTGGGTTTGGGGGT | p.Asn106GlyfsTer20 | p.N106Gfs*20 | P01375 | protein_coding | | | TCGA-B5-A5OD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD |
TNF | insertion | Frame_Shift_Ins | novel | c.316_317insGGGTTAGT | p.Asn106ArgfsTer17 | p.N106Rfs*17 | P01375 | protein_coding | | | TCGA-B5-A5OD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD |
TNF | SNV | Missense_Mutation | | c.291N>T | p.Gln97His | p.Q97H | P01375 | protein_coding | deleterious(0.05) | benign(0.161) | TCGA-ED-A459-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Ancillary | alvesin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | HYDROXYCHLOROQUINE | HYDROXYCHLOROQUINE | 9002011 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | MIDAZOLAM | MIDAZOLAM | 16406030 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | SODIUM CROMOGLYCATE | | 7554404 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CYT-609 | | 20876255 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | ABT-122 | REMTOLUMAB | |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | rifampin | RIFAMPIN | 22151084 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | DLX-105 | | |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | PRAZOSIN HYDROCHLORIDE | | 11406472 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CEFOTAXIME | CEFOTAXIME | 8354907,10989981 |
7124 | TNF | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CPL-7075 | LENABASUM | |